Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 25.16

From 52W high−53.73%

Volume5.82M

Market capCNY 35.52B

P/E (TTM)−89.2x

P/S (TTM)16.6x

Div yield—

Key dataSep 18, 2026

Open

CNY 25.16

From 52W high

−53.73%

Volume

5.82M

Market cap

CNY 35.52B

ValuationView details →

P/E (Fwd)

6.4x

EV/EBITDA

−229.8x

P/E (TTM)

−89.2x

RSI (14)

35.7

MomentumView details →

1D Return

−8.17%

YTD Return

−43.44%

ValuationView details →

P/E (Fwd)

6.4x

P/E (TTM)

−89.2x

EV/EBITDA

−229.8x

EV/Sales

15.6x

P/S (TTM)

16.6x

P/B (TTM)

3.0x

ProfitabilityView details →

Gross Margin

51.30%

Net Margin

−20.01%

EBITDA Margin

−6.77%

ROE (TTM)

−3.29%

ROA (TTM)

−2.82%

Asset Turnover

0.14x

GrowthView details →

Revenue YoY

+2.54%

EPS YoY

—

FCF YoY

−33.09%

Revenue CAGR 3Y

−45.42%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−8.17%

YTD Return

−43.44%

1Y Return

−55.78%

RSI (14)

35.7

vs 50D SMA

−12.04%

vs 200D SMA

−31.37%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

4.21x

Quick Ratio

3.73x

Div Yield

—

Div Rate

—

Div Growth 1Y

−55.20%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.94B

Net Income (TTM)

−388.47M

Op. CF (TTM)

−56.32M

Next earningsOct 23, 2026 →

Latest newsMore news →

Wantai Biological announced plans to terminate its 2021 private placement project for a 20-valent pneumococcal polysaccharide conjugate vaccine and redirect the remaining raised funds of 455 million yuan to a new high-valent pneumococcal polysaccharide conjugate vaccine project with a total investment of 2.437 billion yuan.13d ago

Wantai Biological announced its first-half 2026 results: revenue of 1.048 billion yuan, up 24.29% year-on-year, and a net loss attributable to shareholders of 128 million yuan, compared with a loss of 144 million yuan in the same period last year.32d ago

Similar companies

君实生物-U688180.SH IMBdx461030.KQ 3SBio Inc.01530.HK Shanghai Henlius Biotech, Inc.02696.HK 三生国健688336.SH Alnylam Pharmaceuticals, Inc.ALNY Find similar companies →

Latest newsMore news →

Wantai Biological announced plans to terminate its 2021 private placement project for a 20-valent pneumococcal polysaccharide conjugate vaccine and redirect the remaining raised funds of 455 million yuan to a new high-valent pneumococcal polysaccharide conjugate vaccine project with a total investment of 2.437 billion yuan.13d ago Wantai Biological announced its first-half 2026 results: revenue of 1.048 billion yuan, up 24.29% year-on-year, and a net loss attributable to shareholders of 128 million yuan, compared with a loss of 144 million yuan in the same period last year.32d ago